Generation and Therapeutic Efficacy of Highly Oligomer-Specific β-Amyloid Antibodies

Oligomers of the beta-amyloid (A beta) peptide have been indicated in early neuropathologic changes in Alzheimer's disease. Here, we present a synthetic A beta(20-42) oligomer (named globulomer) with a different conformation to monomeric and fibrillar A beta peptide, enabling the generation of highly A beta oligomer-specific monoclonal antibodies. The globulomer-derived antibodies specifically detect oligomeric but not monomeric or fibrillar A beta in various A beta preparations. The globulomer-specific antibody A-887755 was able to prevent A beta oligomer binding and dynamin cleavage in primary hippocampal neurons and to reverse globulomer-induced reduced synaptic transmission. In amyloid precursor protein (APP) transgenic mice, vaccination with A beta globulomer and treatment with A-887755 improved novel object recognition. The cognitive improvement is likely attributable to reversing a deficit in hippocampal synaptic spine density in APP transgenic mice as observed after treatment with A-887755. Our findings demonstrate that selective reduction of A beta oligomers by immunotherapy is sufficient to normalize cognitive behavior and synaptic deficits in APP transgenic mice.